Scenario 2: Injecting into the joint space without training
The core MeAgain experience is designed around the things GLP-1 users need right away: shot or pill tracking, injection-site history, food logging, protein, fiber, water, symptoms, progress, and medication-level context
To these is now added a new class of oral drugs, tyrosine kinase two inhibitors, such as Deucravacitinib, approved by regulatory authorities to offer potent systemic efficacy with the convenience of oral administration, representing a valid alternative for patients who prefer to avoid injections
When DSIP May Not Be Enough Some sleep problems require intervention beyond what DSIP or any peptide can provide
Patients should choose the site that feels most comfortable and accessible to them, whilst ensuring they rotate between different areas to minimise the risk of injection site reactions
Understanding Tirzepatide's Dual Mechanism as a Stronger Alternative Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, creating a pharmacologically distinct advantage over semaglutide's GLP-1-only signaling
